Development of new therapeutic strategy for EGFR-TKI resistant non-small cell lung cancer.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10258
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Okayama University
• Principal Investigator: Asano Hiroaki 岡山大学, 大学病院, 助教 (70534775)
• Co-Investigator(Kenkyū-buntansha): 佃 和憲 岡山大学, 大学病院, 講師 (20346430)
• Co-Investigator(Renkei-kenkyūsha): TOYOOKA Shinichi 岡山大学, 医歯薬学総合研究科, 教授 (30397880) ; SOU Junichi 岡山大学, 大学病院, 講師 (90559890) ; YAMAMOTO Hiromasa 岡山大学, 大学病院, 助教 (40467733)
• Research Collaborator: SUZAWA Ken ; OTSUKA Tomoaki ; CHEN Haiyang
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺癌 / EGFR-TKI耐性 / ABCB1阻害剤 / Elacrida

Outline of Final Research Achievements

One of the most pressing needs for NSCLC with EGFR mutation is to overcome the acquired resistance to EGFR-TKI targeted therapy. We established EGFR-TKI resistant HCC827, HCC4006 and H1299 cells harboring stem cell-like properties. In these EGFR-TKI resistant cells, we detected overexpression of ABCB1 mRNA. Restoration of sensitivity to chemotherapeutic agent(docetaxel) was observed by knocking down of ABCB1 expression. We further observed the usefulness of 3rd generation ABCB1 inhibitor “Elacrida” to EGFR-TKI resistant lung cancer cells harboring stem cell-like properties.

Free Research Field

外科系臨床医学